114 related articles for article (PubMed ID: 7964963)
1. Multidrug resistance in lymphomas.
Yuen AR; Sikic BI
J Clin Oncol; 1994 Nov; 12(11):2453-9. PubMed ID: 7964963
[TBL] [Abstract][Full Text] [Related]
2. [Correlation of expression levels of multidrug resistance gene 1 (mdr1) mRNA, multidrug resistance-associated protein (MRP), amd P-glycoprotein (P-gp) with chemotherapy efficacy in malignant lymphomas].
Yang X; Jia L; Wei L; Zuo W; Song S
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(17):1177-9. PubMed ID: 12475404
[TBL] [Abstract][Full Text] [Related]
3. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
4. [Detection of P-glycoprotein and its clinical significance].
Tanigawa N; Fujii H
Nihon Rinsho; 1997 May; 55(5):1064-8. PubMed ID: 9155154
[TBL] [Abstract][Full Text] [Related]
5. Expression of the human multidrug resistance gene (MDR1) and prognostic correlation in human osteogenic sarcoma.
Imanishi T; Abe Y; Suto R; Higaki S; Ueyama Y; Nakamura M; Tamaoki N; Fukuda H; Imai N
Tokai J Exp Clin Med; 1994 Sep; 19(1-2):39-46. PubMed ID: 7660382
[TBL] [Abstract][Full Text] [Related]
6. Association of mdr1 gene expression with other prognostic factors and clinical outcome in human breast cancer.
Punyammalee B; Manoromana S; Purisa W; Chariyalertsak S; Rerkamnuaychok B
J Med Assoc Thai; 1997 Sep; 80 Suppl 1():S162-73. PubMed ID: 9347665
[TBL] [Abstract][Full Text] [Related]
7. Establishment and characterization of new cellular lymphoma model expressing transgenic human MDR1.
Findling-Kagan S; Sivan H; Ostrovsky O; Nagler A; Galski H
Leuk Res; 2005 Apr; 29(4):407-14. PubMed ID: 15725475
[TBL] [Abstract][Full Text] [Related]
8. [Expression and clinical significance of mdr-1 gene in lymphoma].
Tian WH; Feng HL; Gao JS; Jiang WQ
Ai Zheng; 2002 Aug; 21(8):910-3. PubMed ID: 12478906
[TBL] [Abstract][Full Text] [Related]
9. [Mechanisms of multidrug resistance in tumor cells and analytical methods for its detection].
Takemura Y; Kobayashi H; Miyachi H
Rinsho Byori; 1998 Aug; 46(8):745-58. PubMed ID: 9760826
[TBL] [Abstract][Full Text] [Related]
10. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
[TBL] [Abstract][Full Text] [Related]
12. [Quantitative analysis of multidrug resistance phenotype in hematological malignancies].
Kobayashi H; Takemura Y
Rinsho Byori; 1998 Apr; 46(4):380-90. PubMed ID: 9594630
[TBL] [Abstract][Full Text] [Related]
13. Clinical reversal of drug resistance.
Goldstein LJ
Curr Probl Cancer; 1995; 19(2):65-124. PubMed ID: 7600845
[TBL] [Abstract][Full Text] [Related]
14. Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference.
Stege A; Priebsch A; Nieth C; Lage H
Cancer Gene Ther; 2004 Nov; 11(11):699-706. PubMed ID: 15375376
[TBL] [Abstract][Full Text] [Related]
15. Clinical relationship between MDR1 gene and gallbladder cancer.
Wang BL; Zhai HY; Chen BY; Zhai SP; Yang HY; Chen XP; Zhao WT; Meng L
Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):296-9. PubMed ID: 15138130
[TBL] [Abstract][Full Text] [Related]
16. Establishment of hepatocellular carcinoma multidrug resistant monoclone cell line HepG2/mdr1.
Chen YB; Yan ML; Gong JP; Xia RP; Liu LX; Li N; Lu SC; Zhang JG; Zeng DB; Xie JG; Yang JY; Yan LN
Chin Med J (Engl); 2007 Apr; 120(8):703-7. PubMed ID: 17517188
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic approaches to reversing multidrug resistance.
Sikic BI
Semin Hematol; 1997 Oct; 34(4 Suppl 5):40-7. PubMed ID: 9408960
[TBL] [Abstract][Full Text] [Related]
18. Modulation of multidrug resistance (MDR) in hematological malignancies.
Covelli A
Ann Oncol; 1999; 10 Suppl 6():53-9. PubMed ID: 10676553
[TBL] [Abstract][Full Text] [Related]
19. A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line.
Bhat UG; Winter MA; Pearce HL; Beck WT
Mol Pharmacol; 1995 Oct; 48(4):682-9. PubMed ID: 7476894
[TBL] [Abstract][Full Text] [Related]
20. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
